Please login to the form below

Not currently logged in
Email:
Password:

J&J appoints quality-control chief

Johnson & Johnson has created a new position at the company to oversee all quality, manufacturing and compliance issues 

In the wake of a series of major recalls of its nonprescription medicines, Johnson & Johnson (J&J) has created a new position at the company to oversee all quality, manufacturing and compliance issues.

Ajit Shetty, who is chairman of the board and managing director of the J&J subsidiary Janssen Pharmaceutica, has been tapped to fill the new post. He will serve as a corporate vice president of J&J, reporting directly to company CEO William Weldon, and will oversee quality improvement efforts for J&J's pharmaceutical, consumer products, medical device and diagnostics groups.

Shetty has been with J&J since 1976. He was raised in India but holds an MBA from Carnegie Mellon University in the US, as well as a PhD from Trinity College/Cambridge University in the UK.

In addition, J&J said it has appointed chief quality officers for each of its three major business units. Those positions will report to Shetty.

The recalls, which caused a PR crisis for J&J, involved Children's Tylenol, Motrin and St Joseph aspirin, the allergy drug Benadryl, the antacid Rolaids and Simply Sleep pills.

The products were manufactured at a Pennsylvania factory that has been temporarily shuttered, as well as at another facility in Puerto Rico. Some products were contaminated with bacteria, while others were made with the wrong amount of active ingredient, and still others contained metal shavings.

19th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics